These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 6198637)
1. [Induction of remission in patients with non-Hodgkin lymphomas with high degree of malignancy - preliminary comparison of 2 chemotherapy programs: CHOP-B (cyclophosphamide, adriamycin, vincristine, encorton, bleomycin) and MEV-A (methotrexate, cyclophosphamide, vincristine and adriamycin)]. Walewski JA Nowotwory; 1983; 33(3):259-65. PubMed ID: 6198637 [No Abstract] [Full Text] [Related]
2. [Results of treating lymphomas with high degree of malignancy using COPP, CHOP-Bleo and MEV protocols]. Płuzańska A; Krykowski E; Robak T; Oliskiewicz W; Polkowska E; Dowgier I; Hyjek E Pol Tyg Lek; 1982 Sep; 37(36):1049-53. PubMed ID: 6189105 [No Abstract] [Full Text] [Related]
3. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis. Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406 [TBL] [Abstract][Full Text] [Related]
4. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851. Gottlieb AJ; Anderson JR; Ginsberg SJ; Bloomfield CD; Norton L; Barcos M; Peterson BA; Nissen N; Henderson ES; Holland JF Cancer; 1990 Nov; 66(9):1888-96. PubMed ID: 1699653 [TBL] [Abstract][Full Text] [Related]
5. CHOP vs MEV for the treatment of non-Hodgkin's lymphoma of unfavourable histopathology: a randomized clinical trial. Hagberg H; Björkholm M; Glimelius B; Lindemalm C; Mellstedt H; Killander A Eur J Cancer Clin Oncol; 1985 Feb; 21(2):175-9. PubMed ID: 3886392 [TBL] [Abstract][Full Text] [Related]
6. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis. Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251 [TBL] [Abstract][Full Text] [Related]
7. [Results of treatment of the lymphoblastic and immunoblastic malignant lymphomas using the CHOP-bleo protocol (cyclophosphamide, doxorubicin, vincristine, bleomycin and prednisolone)]. Płuzańska A; Kowalczyński M; Polkowska E; Stempczyńska J; Hyjek E Pol Arch Med Wewn; 1982; 68(1-2):55-64. PubMed ID: 6186997 [No Abstract] [Full Text] [Related]
8. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma. Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407 [TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for large-cell lymphoma: optimism and caution. Coleman M Ann Intern Med; 1985 Jul; 103(1):140-2. PubMed ID: 2408529 [No Abstract] [Full Text] [Related]
10. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619 [TBL] [Abstract][Full Text] [Related]
11. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764 [TBL] [Abstract][Full Text] [Related]
12. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study. Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168 [TBL] [Abstract][Full Text] [Related]
13. [CHOP-bleo versus m-BACOD in the treatment of intermediate and high-grade malignant lymphomas]. Avilés A; Huerta J; Guzmán R; Zepeda G; Díaz-Maqueo JC Rev Invest Clin; 1990; 42(4):271-6. PubMed ID: 1708910 [TBL] [Abstract][Full Text] [Related]
14. A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (adriamycin), vincristine, and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: preliminary report of Cancer and Leukemia Group B Study 7851. Ginsberg SJ; Anderson JR; Gottlieb AJ; Bloomfield CD; Norton L; Barcos M; Holland JF NCI Monogr; 1987; (5):77-80. PubMed ID: 2448657 [TBL] [Abstract][Full Text] [Related]
15. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients. Todeschini G; Ambrosetti A; Meneghini V; Pizzolo G; Menestrina F; Chilosi M; Benedetti F; Veneri D; Cetto GL; Perona G J Clin Oncol; 1990 May; 8(5):804-8. PubMed ID: 1692089 [TBL] [Abstract][Full Text] [Related]